[
  {
    "ts": null,
    "headline": "PTC Therapeutics to Participate at Upcoming Investor Conferences",
    "summary": "PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:",
    "url": "https://finnhub.io/api/news?id=5b98d8e97053834317a882102b63e5133798ce0e9723ecb66b2e5be85bd460f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771851600,
      "headline": "PTC Therapeutics to Participate at Upcoming Investor Conferences",
      "id": 139183971,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PTC",
      "source": "Yahoo",
      "summary": "PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:",
      "url": "https://finnhub.io/api/news?id=5b98d8e97053834317a882102b63e5133798ce0e9723ecb66b2e5be85bd460f7"
    }
  },
  {
    "ts": null,
    "headline": "How Sephience Is Reshaping The Story For PTC Therapeutics (PTCT) And Analyst Expectations",
    "summary": "Analysts have adjusted their fair value estimate for PTC Therapeutics slightly lower, from US$88.50 to about US$87.93, keeping price targets clustered in the low to mid US$80s. This small move reflects how recent Street research is balancing optimism around Sephience with caution on DMD pressure and longer term growth visibility. As you read on, you will see how these shifting targets and narratives might shape how you follow PTC from here. Stay updated as the Fair Value for PTC Therapeutics...",
    "url": "https://finnhub.io/api/news?id=ef8cf9cdb3a2672764a9821003fa1ebe476f2fe6f6d15cc92f64a18bb2e91a82",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771826835,
      "headline": "How Sephience Is Reshaping The Story For PTC Therapeutics (PTCT) And Analyst Expectations",
      "id": 139181693,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PTC",
      "source": "Yahoo",
      "summary": "Analysts have adjusted their fair value estimate for PTC Therapeutics slightly lower, from US$88.50 to about US$87.93, keeping price targets clustered in the low to mid US$80s. This small move reflects how recent Street research is balancing optimism around Sephience with caution on DMD pressure and longer term growth visibility. As you read on, you will see how these shifting targets and narratives might shape how you follow PTC from here. Stay updated as the Fair Value for PTC Therapeutics...",
      "url": "https://finnhub.io/api/news?id=ef8cf9cdb3a2672764a9821003fa1ebe476f2fe6f6d15cc92f64a18bb2e91a82"
    }
  }
]